Specific Biologics raises $35M
- Company
- Specific Biologics
- Funding stage
- Undisclosed
- Amount
- $35-million
- Date
- Location
- 🇨🇦 Toronto, Canada
- Sector
- Gene Editing
- Investors
- Undisclosed
What happened
Toronto-based Specific Biologics, a Western University spinout, raised $35 million to advance its gene-editing therapy for ALS. The funding follows promising pre-clinical results.
Why it matters
Pre-clinical university spinouts securing mid-eight-figure rounds demonstrate ongoing capital commitment to deep-tech therapeutics targeting severe neurodegenerative diseases like ALS. Securing $35 million provides the runway necessary to transition proprietary platform assets into initial human clinical trials.
What to watch
Regulatory submissions and timeline milestones for advancing the ALS gene-editing therapeutic into Phase 1 clinical trials.
VCBites Signal
Why this score: A $35 million financing for a university spinout signals solid support for pre-clinical assets, though undisclosed investors and round stage limit the signal strength.
VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.
Who should care?
- Biotech Founders
- Healthcare Investors
- Gene Editing
- Deep Tech VC
Source
This is an original short summary. Read the full reporting at the original source.
Read the original story on Globe and Mail — Report on BusinessShare the signal
VC Bites
Specific Biologics raises $35M
VCBITES SIGNAL: 33 / 100
Why it matters
Pre-clinical university spinouts securing mid-eight-figure rounds demonstrate ongoing capital commitment to deep-tech therapeutics targeting severe neurodegenerative diseases like ALS. Securing $35 million provides the runway necessary to transition proprietary platform assets into initial human clinical trials.
VC Bites · Venture capital signals, explained.
The post text is copied to your clipboard so you can paste it alongside the link.